← Evidence library

BIB_451

Metformin & melanoma — the CALIBRATED "if HbA1c returns pre-diabetic, metformin has aligned metabolic + melanoma signal; NOT a standalone chemoprevention for non-diabetics" entry. Fills a ZERO-coverage gap (no prior BIB on metformin in any context). Primary anchor: Feng et al. 2024 Frontiers in Oncology systematic review + meta-analysis (most recent, most comprehensive synthesis). Key signals: Stage I/II 5-year recurrence 32.3% vs 47.7% with vs without metformin (p=0.012); brain metastasis rate 8.9% vs 14.6% (p=0.039); overall survival numerically improved but NS. Mechanism: AMPK → mTOR inhibition (anti-proliferative) + mitochondrial complex I inhibition + enhanced CD8+ T-cell fitness in hyp

Evidence grade

B

Tier

2 (systematic review + meta-analysis of observational cohorts; observational evi

Cited by tasks

10, 22a

Identifiers

PMC10312386 · DOI:10.3389/fonc · PMID:32980534

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_451/findings.md (research corpus). This page is a short context summary — not individualised medical advice.